Medical Device Sales Strategy: Build the Committee’s Case From the First Meeting

The classic medical device sales strategy runs through the clinician. Find the surgeons who would benefit, get the product in their hands, and let their enthusiasm carry it into the hospital. That still matters. A clinician who wants your product is usually how it gets considered at all.

But in most hospitals, considered is not the same as bought. New products are routed through a value analysis process, where supply chain, finance, nursing, infection prevention and clinical leads weigh total cost, evidence and the disruption of switching, often against a competitor already on a purchasing contract. The clinician's yes gets you into that room. It does not decide what happens there.

So the strategic question is when you start building the committee's case. Most reps start after the surgeon says yes, which means assembling evidence and economics in a hurry, for a meeting they will not attend. The alternative is to build it from the first meeting. This guide covers how: mapping who will ask what, designing evaluations that produce a decision, dealing with purchasing contracts, what marketing should actually produce, and how the picture differs in Europe.

We covered the objections the committee raises, and how to train reps to answer them, in medical device sales training. This guide is about the strategy around them.

Why the clinician's yes isn't the decision

Value analysis committees exist because hospitals decided that product choices with large cost consequences should not rest on individual preference. They bring clinical, financial and operational views into one room. Three features of that room shape everything else:

• You are usually not in it. Your clinical champion presents, often briefly, among other agenda items.
• The questions are mostly economic and operational. Cost per case, total cost of use, training burden, standardisation, contract status.
• It meets on a schedule. Miss the deadline for a meeting, or arrive with an incomplete file, and the decision can slip by a full cycle.

The parallel in pharmaceutical sales is the formulary committee, and the same logic applies: much of the decision has moved away from the individual clinician. We covered that shift in pharmaceutical sales strategy.

Map the committee before you need it

Committee membership varies by hospital, but these roles are common. Each asks a different question, and each needs something different from you.

Role	Asks	Bring
Clinical lead	Does it improve outcomes?	Evidence, honestly summarised
Nursing	What changes for my team?	Workflow, training plan
Supply chain	Is it on contract? Can we stock it?	Contract status, logistics
Finance	What does it cost per case?	A cost-per-case model
Infection prevention	Is it safe to reprocess?	Cleaning and sterilisation data
Biomedical / IT	Will it connect and be serviced?	Technical and service detail

The useful habit is to treat this table as a checklist from the first conversation. Each discovery meeting, with the surgeon, the theatre manager or a buyer, is a chance to learn what one of these people will care about, and to find out who actually sits on this hospital's committee. Ask your champion directly: "Who's on the committee, and what did they push back on last time something new came through?"

Build the committee's file from day one

Start a document on the first meeting and title it as what it will become: the submission your champion will take to the committee. Each section maps to one of the questions above. Fill it in as you learn, rather than writing it all in the week before the meeting.

A good file usually contains:

1. The clinical problem, in the hospital's own terms, with their numbers where you have them.
2. The evidence, summarised honestly, including its limits.
3. Cost per case, modelled with their volumes, against current practice.
4. What changes operationally: training, trays, stocking, reprocessing.
5. Contract position and how the purchase would be made.
6. The evaluation proposal, with agreed success criteria (below).
7. A one-page summary your champion can present in five minutes.

Then work backwards from the meeting date. When is the next committee meeting? When is the submission deadline? What has to be true, and who has to have seen what, by then? That turns a vague "it's going to committee" into a dated plan, the same discipline as a mutual action plan.

Start the committee's file at the first meeting, not after the surgeon says yes. By the time the clinician is convinced, the committee's questions should already have answers.

Evaluations that end in a decision

Product evaluations and trials are where many device deals stall. The product goes in, clinicians use it, impressions are gathered, and the result is a collection of opinions that the committee can interpret any way it likes. Evaluations that never end are a common way for a deal to die politely.

The fix is to agree the decision rule before the evaluation starts, in writing, with the champion and ideally with someone from supply chain or the committee:

• Which cases and how many, so the sample is defined in advance.
• Which measures count: procedure time, a specific complication, staff feedback on defined questions, cost per case.
• What result means yes. "If procedure time is no worse and staff rate ease of use at least as high as the current product, we move to a contract discussion."
• Who judges, and by when. A named person and a date for the decision.

An evaluation designed this way produces a decision either way. If the result is no, you find out quickly and cheaply. If it is yes, the committee has evidence it agreed to in advance, which is very hard to argue against.

"We're on contract": purchasing groups and incumbents

In the United States, most hospitals buy many products through group purchasing organisations, which negotiate contracts with suppliers on behalf of their member hospitals. Suppliers usually pay the purchasing organisation an administrative fee, and hospitals often have commitments to buy a share of a category through contracted suppliers. The practical result is that "we're on contract with someone else" is the default position for many products, not an unusual objection.

There are several routes around it, each with its own cost and timescale:

• Win a purchasing contract. The long, strategic route, usually at the company level rather than a rep's. Contract periods are typically several years, so knowing when the relevant contract is up for renewal matters.
• A local agreement with the hospital or health system, where the hospital's own process allows buying off contract with justification.
• A narrow first use. A defined subset of cases where the contracted product genuinely underperforms, small enough not to threaten the hospital's contract commitments.
• Timing. If the incumbent's contract renews in eighteen months, that date may be the real decision point, and the work now is to be the obvious choice when it arrives.

Treat contract status as something to establish in the first or second conversation, not something discovered when the committee asks. For how to handle the conversation itself, see we already have a vendor and our guide to selling to a head of procurement.

Marketing's real job here

In many device companies, marketing is measured on leads. In this kind of sale, leads are rarely the constraint. The constraint is the committee file, and marketing is well placed to build the parts of it that should not be reinvented for every hospital:

• An evidence summary that a clinical lead will trust: study design, sample size, endpoints, comparator and limitations, not just headline results.
• A cost-per-case model that a rep can fill in with a hospital's own volumes and current costs.
• Operational fact sheets: reprocessing, storage, training time, service.
• A committee summary template a champion can adapt and present.

This is what the phrase medical device sales and marketing should mean in practice: marketing producing the materials the committee needs, so reps spend their time on the hospital-specific parts.

Europe: tenders instead of committees

In much of Europe, hospital purchasing works differently. Public hospitals are generally bound by public procurement rules, which in the European Union come from a 2014 directive and its national implementations, while the United Kingdom now has its own procurement legislation. Larger purchases go through formal tenders, sometimes run by regional or national purchasing bodies rather than individual hospitals.

That changes the strategy in three ways:

• The decisive work happens before the tender is published. The specification and award criteria are written first, and the rules allow buyers to consult the market in advance. Once a tender is live, contact with the buyer is restricted to the formal process.
• Award criteria are not only price. EU rules require contracts to be awarded on the most economically advantageous tender, which can weigh quality, clinical value and total cost alongside price. Helping buyers understand which criteria actually matter clinically is legitimate, early work.
• Contracts run for years. Losing a tender can mean waiting for the next one, so knowing the procurement calendar is as important as knowing the clinicians.

The rules differ by country and change over time. Treat this as orientation and check the specifics with someone who knows the market you are selling into.

Practising the committee case

Two conversations decide most device deals, and both are rehearsable. The first is the rep's discovery with each role: asking the finance lead about cost per case, or infection prevention about reprocessing, without sounding like a clinical salesperson out of their depth. The second is the champion's five minutes in front of the committee, which most champions present unrehearsed.

Where our tool fits

We build an AI practice tool, so read this with that in mind.

SalesArmor lets device reps rehearse conversations with the different people on a committee, such as a surgeon, a supply chain lead or a finance director, and get scored afterwards. It can also be used to run through the committee presentation before the champion gives it. See our medical device sales page and our comparison of AI roleplay tools for medical device sales.

Common questions about medical device sales strategy

What is a medical device sales strategy? It is the plan for getting a device chosen and bought by hospitals and other providers: which clinicians and accounts to prioritise, how to build the clinical and economic case the hospital's committee will review, how to handle existing purchasing contracts, and how to design evaluations that lead to a decision.

What is a value analysis committee? It is a group within a hospital or health system that reviews new products before purchase, usually including clinical leads, nursing, supply chain, finance and other specialists. It weighs evidence, total cost, operational impact and contract position, and the vendor is often not present when it decides.

How do you get a medical device through a value analysis committee? Build the committee's file from the first meeting: the clinical problem in the hospital's terms, honest evidence, a cost-per-case model using their volumes, operational changes, contract position, an evaluation with agreed success criteria and a short summary your clinical champion can present.

What is a GPO in medical device sales? A group purchasing organisation negotiates contracts with suppliers on behalf of member hospitals in the United States. Hospitals often commit to buying a share of a category through contracted suppliers, which is why being off contract is a common obstacle for new devices.

How do you sell a medical device when the hospital is on contract with a competitor? Options include winning a purchasing contract at company level, a local agreement where the hospital allows off-contract purchases with justification, a narrow first use where the incumbent underperforms, or preparing to be the obvious choice when the current contract comes up for renewal.

How should medical device evaluations be designed? Agree the decision rule before starting: which cases and how many, which measures count, what result means yes, and who decides by when. That turns an open-ended trial into a decision either way, and gives the committee evidence it accepted in advance.

How is medical device sales different in Europe? Public hospitals in Europe generally buy through formal tenders under public procurement rules, often run by regional or national bodies. The decisive work happens before a tender is published, award criteria can weigh quality and total cost alongside price, and contracts typically run for several years.

What is the role of marketing in medical device sales? Beyond generating interest, marketing is well placed to produce the materials every committee needs: an honest evidence summary, a cost-per-case model reps can tailor, operational fact sheets and a committee presentation template, so reps can focus on the hospital-specific case.

A note on sources

This guide publishes no figures on committee approval rates, group purchasing market shares, the share of hospital spending on particular product categories, or tender outcomes. We could not find primary sources for the commonly quoted versions.

The description of group purchasing organisations is general and US-specific. The European section draws on the general principles of the EU's 2014 public procurement directive, including market consultation before a tender and award on the most economically advantageous tender; national rules and the UK's own legislation differ. None of this is legal or procurement advice. The committee map, the day-one file and the evaluation decision rule are ours.